Oryzon to Present its LSD1 program in Acute Leukemias at the GTC’s 2nd Epigenetics in Drug Discovery conference in Boston
Drugs from ORYZON shown to be efficacious in the treatment of Acute Leukemia
Oryzon to attend BIO-Europe Spring 2012 Conference in Amsterdam
Oryzon participates in a R&D European consortium in Parkinson’s disease
Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease
Early diagnostic in cancer is essential to obtain more effective treatments for the disease. ORYZON has performed extensive genomic surveys in several cancers.
Our current product pipeline is:
